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Abstract
Background: Microtubules are considered major therapeutic targets in patients with breast cancer. In spite of their
essential role in biological functions including cell motility, cell division and intracellular transport, microtubules
have not yet been considered as critical actors influencing tumor cell aggressivity. To evaluate the impact of
microtubule mass and dynamics on the phenotype and sensitivity of breast cancer cells, we have targeted tubulin
binding cofactor C (TBCC), a crucial protein for the proper folding of a and b tubulins into polymerization-
competent tubulin heterodimers.
Methods: We developed variants of human breast cancer cells with increased content of TBCC. Analysis of
proliferation, cell cycle distribution and mitotic durations were assayed to investigate the influence of TBCC on the
cell phenotype. In vivo growth of tumors was monitored in mice xenografted with breast cancer cells. The
microtubule dynamics and the different fractions of tubulins were studied by time-lapse microscopy and lysate
fractionation, respectively. In vitro sensitivity to antimicrotubule agents was studied by flow cytometry. In vivo
chemosensitivity was assayed by treatment of mice implanted with tumor cells.
Results: TBCC overexpression influenced tubulin fraction distribution, with higher content of nonpolymerizable
tubulins and lower content of polymerizable dimers and microtubules. Microtubule dynamicity was reduced in
cells overexpressing TBCC. Cell cycle distribution was altered in cells containing larger amounts of TBCC with
higher percentage of cells in G2-M phase and lower percentage in S-phase, along with slower passage into
mitosis. While increased content of TBCC had little effect on cell proliferation in vitro, we observed a significant
delay in tumor growth with respect to controls when TBCC overexpressing cells were implanted as xenografts in
vivo. TBCC overexpressing variants displayed enhanced sensitivity to antimicrotubule agents both in vitro and in
xenografts.
Conclusion: These results underline the essential role of fine tuned regulation of tubulin content in tumor cells
and the major impact of dysregulation of tubulin dimer content on tumor cell phenotype and response to
chemotherapy. A better understanding of how the microtubule cytoskeleton is dysregulated in cancer cells would
greatly contribute to a better understanding of tumor cell biology and characterisation of resistant phenotypes.
Background
Microtubules are crucial structures for living cells as
they are involved in many biological functions including
cell motility, cell division, intracellular transport, cellular
architecture as well as other cell types specific functions
[1]. Their dynamic property involved in cell division
makes out of microtubules major targets for anticancer
drugs. The drugs commonly used are divided into two
main families of taxanes and vinca alkaloids which are
known to suppress microtubule dynamics by stabilizing
or destabilizing the microtubules respectively and thus
inhibiting the metaphase anaphase transition, blocking
mitosis and inducing apoptosis [2]. Taxanes and vinca
alkaloids are among many drugs used to treat breast
cancer [3]. However, resistance to anticancer drugs is
appearing, inducing a need to understand and identify
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responsible of the resistance phenotype is the alteration
in the dynamic properties of microtubules. Microtubules
have two main dynamic behaviors. First they exhibit a
dynamic instability which consists of apparently random
transitions between slow elongation and rapid shorten-
ing states [4]. Another important property is the tread-
milling by which tubulin subunits continuously flux
from one end of the polymer to the other, due to net
differences in the critical subunit concentrations at the
opposite microtubule ends [5].
Microtubules are made of a/b-tubulin heterodimers
whose proper folding involves many chaperonins as well
as protein cofactors [6,7]. After being synthesized, the
tubulins are sequestered by cytosolic chaperonins for
their correct folding and preparation for further interac-
tions with the tubulin binding cofactors TBC [8,9]. The
proper folding pathways of a-tubulin and b-tubulin into
the dimers are interdependent and five TBC (TBCA to
TBCE) are involved. TBCB and TBCA bind to a-a n db-
tubulins respectively and the formed complexes serve as
reservoirs of tubulin peptides in the cytoplasm [10,11].
The a-a n db-tubulins are then delivered to TBCE and
TBCD respectively where they form a supercomplex with
TBCC (TBCE/a-tubulin/TBCC/TBCD/b-tubulin). After
hydrolysis of GTP by b-tubulin, this complex releases
activated a/b-tubulin heterodimers which can readily
polymerize into microtubules [10,12,13].
Little is known regarding the role of TBCs in cancer. It
has been shown that the inhibition of TBCA in MCF7 and
HeLa cells modified the microtubule structures, caused
cell cycle arrest in G1 and cell death [14]. TBCB and
TBCE have been found to physically interact and induce
microtubule depolymerization in vitro [15]. In addition to
their roles in the proper folding of microtubules, these
cofactors might have other roles involving microtubules. It
was recently shown that microtubules contribute to the
mechanism of cell detachment through TBCD by trans-
porting it to the cell membrane where it interacts with
adherent and tight junctions [16]. It has been described
that TBCD interacts with Arl2, ADP ribosylation factor
like 2 (Arl2) which dissociates it from the a/b tubulin het-
erodimers [17]. A study in Arabidopsis thaliana showed
that TBCC plays an important role in releasing competent
a/b-tubulin polymerizable heterodimers [18,19]. Another
study performed in X-linked retinitis pigmentosa 2 (RP2)
showed that RP2 responsible for the progressive degenera-
tion of the photoreceptor cells and TBCC have similar
sequences. Both of these proteins were found to be activa-
tors of GTPases but only TBCC is capable of catalyzing
the heterodimerization of tubulins [20].
Since TBCC is crucial for the proper folding of tubu-
lins and their polymerization into microtubules and
since little is known about this protein with respect to
breast cancer, we were interested in studying the impact
of TBCC overexpression on the phenotype of tumor
cells as well as on microtubule content and dynamics
and response to antimicrotubule drugs. We have found
that overexpressing TBCC influenced cell cycle distribu-
tion of breast cancer cells in our model along with an
increase in percentage of cells in G2-M phase of cell
cycle and a slower mitosis. The dynamics of microtu-
bules were reduced and the content of polymerizable
tubulins was decreased. Finally, cells overexpressing
TBCC were more sensitive to microtubules targeting
agents both in vivo and in vitro.
Methods
Plasmid construction
The pcDNA6/V5-His A plasmid was used to clone the
1k bh u m a nTBCC cDNA (NM_003192) extracted from
hTerT-HME-1 human mammary epithelium cells
(ATCC). The mRNA was extracted using Trizol reagent
(Invitrogen, Cergy Pontoise, France) following the man-
ufacturer’s instructions. Reverse transcription into
cDNA was then done using Moloney leukaemia virus
reverse transcriptase (Invitrogen, Cergy Pontoise,
France) for 1 hour at 37°C as described in the manufac-
turer’s manual. The cDNA obtained was then amplified
by the full length TBCC forward GCCAATATG-
GAGTCCGTCAG and reverse CAACTGCTTAGTCC-
CACTGGA primers using a high fidelity polymerase
according to the manufacturer’s instructions (Jena
Bioscience, Germany). The PCR conditions were 30
cycles of denaturation at 94°C for 1 min, annealing at
60°C for 1 min and elongation at 72°C for 1 min. Puri-
fied amplicon was subcloned into pGEMTeasy and
thereafter into pcDNA6 in the sense orientation (desig-
nated as pcDNA6/C+) using EcoRI (Fermentas, France).
Cell culture and transfections
MCF7 (human mammary adenocarcinoma, ATCC) cells
and transfectants were grown in DMEM supplemented
with penicillin (200 UI/ml), streptomycin (200 μg/ml)
and fetal bovine serum (10%) at 37°C in a humidified
atmosphere containing 5% CO2. Cells were transfected
with pcDNA6/C+ or empty pcDNA6 using lipofectin
(Invitrogen, Cergy Pontoise, France) following the manu-
facturer’s instructions. The stable transfectants were
obtained through blasticidin selection (20 μg/ml) (KN-
1004, Euromedex, France). Cloning of the populations of
cells was performed for each of the two batch popula-
tions and 3 clones representative of each population were
selected for further characterization, on the basis of their
differential levels of expression of the protein TBCC. The
clones designated MC+1, MC+2 and MC+3 represent
the clones overexpressing TBCC. The clones designated
MP6.1, MP6.2 and MP6.3 represent the control clones.
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Protein extraction and western blot analysis were per-
formed as described previous l y[ 2 1 ] .T h ea n t i b o d i e s
used were anti b III-tubulin (clone Tuj1, 1/2500; Cova-
lab, Lyon, France), anti p53 (clone DO7, 1/1000; Dako,
Denmark), anti b-actin (clone AC-15, 1/5000), anti a-
tubulin (clone DM1A, 1/1000), anti b-tubulin (clone 2.1,
1/1000), anti tyrosinated a-tubulin (clone TUB-1A2, 1/
1000) and acetylated a-tubulin (clone 6-11B-1, 1/1000)
from Sigma Aldrich (St Quentin Fallavier, France). The
polyclonal antibodies against TBCC (1/800) and TBCD
(1/3000) were generously provided by N. Cowan (New
York University Medial Center, USA) and those against
Arl2 (1/1000) and Glu-tubulin (1/1000) were generously
provided by R. Kahn (Emory University School of Medi-
cine, Atlanta, USA) and L. Lafanechère (Centre de Cri-
blage pour des Molécules Bio-Actives, Grenoble),
respectively. Expression levels of the proteins were stan-
dardized against the b-actin.
RNA interference assays
A desalted duplex siRNA targeting TBCC 5’-CUGAG-
CAACUGCACGGUCA-3’ and its corresponding
scrambled sequence were designed by Sigma-Aldrich (St
Quentin Fallavier, France). The siRNAs (200 nM) were
transfected into 25 × 10
4 of MCF7, MP6.1 or MC+1
cells using oligofectamine (Invitrogen, Cergy Pontoise,
France) according to the manufacturer’sp r o t o c o lo n
two consecutive days. Protein analyses by western blot
or flow cytometry experiment were done on the third
day after transfection.
Cell proliferation analysis
Cell proliferation was estimated using the methylthiazo-
letetrazolium (MTT) and BrdU assay. For the MTT test,
cells (13 × 10
4) were seeded in a 6-well plate and incu-
bated at 37°C. Every 24 h and for one week, MTT (3 mg)
was added to each well of each plate. After 2 hrs of
incubation at 37°C, supernatants were removed, forma-
zan crystals solubilized with 3 ml of isopropanol-
HCl-H2O (90:1:9, v/v/v) and plates scanned. The absor-
bance was measured spectrophotometrically with a
microplate reader (Labsystem Multiskanner RC) and the
MTT values were obtained as subtraction of absorbances
read at 540 and 690 nm wavelengths. The nonradioactive
BrdU-based cell proliferation assay (Roche, Basel, Swit-
zerland) was performed according to the manufacturer’s
protocol. Treated and untreated cells (5 × 10
3 cells per
well) were seeded in a 96-well plastic plate and the assay
was performed after 48, 72, 96 and 168 hours. Treated
cells were exposed to either 0.5 nM or 1 nM of gemcita-
bine (Lilly, IN, USA) for one week. BrdU incorporation
into the DNA was determined by measuring the absor-
bance at 450 on an ELISA plate reader.
Analysis of cell cycle distribution by flow cytometry
Cells were incubated 24 h with either 10 nM Paclitaxel
(Bristol-Myers Squibb, New York, USA) or 1 nM vinor-
elbine (Pierre Fabre medicaments, Boulogne, France).
Treated and untreated cells were then collected and
incubated 1 hour at 4°C with propidium iodide (0.05
mg/ml) solution containing Nonidet-P40 (0.05%). Cells
were analyzed using a FACS Calibur flow cytomoter
( B DB i o s c i e n c e sE u r o p e ,E r e m b o d e g e m ,B e l g i u m )a n d
cell cycle distribution was determined using Modfit LT
2.0™ software (Veritysoftware Inc, Topsham, USA). For
the siRNA’s transfected clones, the cell cycle was studied
48 h after the first transfection.
Long time-lapse microscopy and analysis of mitosis
Cells (3 × 10
5) were seeded in a 35 mm cell culture
dish, placed in culture medium maintained at 37°C in a
5% CO2 atmosphere and observed using an inverted
time lapse microscope (Olympus IX50) at the Centre
Commun de Quantimétrie (Université Claude Bernard
L y o n ,F r a n c e ) .I m a g e sw e r e acquired every 2 minutes
for 24 hours using a numerical CFW-1308M 1360X1024
camera (Scion, Frederick, USA) driven by ImageJ soft-
ware (NIH, Bethesda, USA). 30 complete mitoses were
analysed for each of the MP6.1 and MC+1 clones using
ImageJ software (NIH, Bethesda, USA).
Immunofluorescence
Cells (MP6.1 and MC+1) exposed or not to 10 nM of
paclitaxel for 24 hours were fixed by 4% paraformaldehyde
during 15 minutes at room temperature and permeabilized
using a PBS-Triton X-100 0.1% solution. Non specific sites
were blocked using a solution containing 0.1% bovine
serum albumin and 1% fetal calf serum. Cells were incu-
bated with either a 1:100 of an antibody against b-tubulin
(clone 2.1, Sigma Aldrich) or a 1:30 dilution of a monoclo-
nal antibody against TBCC (Abnova, Taiwan) followed by
a secondary FITC-antibody (Dako, Denmark). DNA stain-
ing was performed using diaminido-phenyl-indol (DAPI)
(Roche, Manheim, Germany).
Images were obtained using a laser scanning confocal
TCS Sp2 DMRXA microscope x63 objective (Leica
Microsystems; Wetzlar, Germany) at the Centre Com-
mun de Quantimétrie (Université Claude Bernard Lyon,
France).
Separation and quantification of soluble unfolded
tubulins, polymerizable ab-tubulin heterodimers and
microtubules
Cells (20 × 10
6) were harvested and lysed in 200 μlo f
buffer (100 mM Pipes, pH 6.7, 1 mM EGTA, and 1 mM
MgSO4) by two freeze-thaw cycle. Lysed cells were cen-
trifuged at 12,000 × g for 15 minutes at 4°C. The super-
natant was then ultracentrifuged (100,000 × g for 1 h at
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ble tubulins” and a pellet containing “microtubules”. The
microtubule fraction was resuspended in 100 μlo fl y s i s
buffer and 100 μl of the supernatant were incubated
with 1 mM of GTP at 35°C for 30 minutes to allow
tubulin polymerization then ultracentrifuged at 50,000 ×
g for 45 minutes at 35°C. The resulting pellet contained
the “polymerizable tubulin” (PT) heterodimers and the
supernatant contained “nonpolymerizable tubulin”
(NPT) heterodimers, included tubulin peptides com-
plexed with tubulin binding cofactors. The different
fractions of tubulins were run on silver stained gels fol-
lowing manufacturer’s recommendations (Amersham
Biosciences AB, Sweden). After coloration, the single
band observed at 55 kDa for the polymerizable tubulin
heterodimers confirmed the success of purification (data
not shown). The experiment was performed in triplicate
using the two cell lines MP6.1 and MC+1. Densito-
metric quantification of western blots was performed
with ImageJ software (NIH, USA).
Time lapse fluorescent microscopy and analysis of
microtubule dynamics
Cells (3 × 10
5) were seeded in 6-well plate with circular
glasses of 24 mm in their bottom and transfected with
the pAcGFP1-tubulin vector (Clontech) using lipofectin
(Invitrogen) following the manufacturer’si n s t r u c t i o n s .
The glasses containing the cells were placed in culture
medium maintained at 37°C in a 5% CO2 atmosphere in
a time lapse inverted microscope (Olympus IX50) at the
Centre Commun de Quantimétrie (Lyon, Université
Claude Bernard, France). Cells were imaged with a
numerical CFW-1308M 1360X1024 camera (Scion, Fre-
derick, USA) driven by imageJ software (NIH, Bethesda,
USA) using a 40× oil immersion lens (Zeiss, Göttingen,
Germany). 30 pictures of the cell’s microtubules were
taken at 4 seconds intervals. The positions of the plus-
ends of individual MT in peripheral lamellar regions of
cells were tracked over time using ImageJ® software and
graphed using Microsoft® Excel spreadsheet as position
versus time to generate a ‘life-history plot’ for each MT.
Growth and shortening rates and durations were derived
by regression analysis. A difference of >0.5 μmb e t w e e n
any two consecutive points was considered as a growth
or shortening event. Transitions into depolymerisation
or shortening are termed catastrophes, and transitions
from shortening to growth or pause are called rescue.
The catastrophe and rescue frequencies per unit time
were calculated by dividing respectively the number of
transitions from growth and pause to shortening and
the number of transitions form shortening and pause to
growth by the sum of the time in growth and pause.
Dynamicity represents total tubulin exchange at the MT
end and was calculated by dividing the sum of total
length grown and shortened by the MT life span. The
experiment was performed twice on 50 microtubules of
the two clones MP6.1 and MC+1.
In vivo growth analysis
Female CB17/SCID mice purchased from Charles River
Laboratories (Arbresle, France) were bred under patho-
gen-free conditions at the animal facility of our institute.
Animals were treated in accordance with the European
Union guidelines and French laws for the laboratory ani-
mal care and use. The animals were kept in conven-
tional housing. Access to food and water was not
restricted. All mice used were 5 to 6 weeks old at the
time of cells injections. This study was approved by the
local animal ethical committee. Mice were divided into
six groups of six mice each which corresponds to the
injections of MP6.1, MP6.2, MP6.3, MC+1, MC+2 and
MC+3 cells. 3 × 10
6 cells were injected subcutaneously
in mice with 50% matrigel (BD Biosciences, Belgium).
The six mice were divided into two groups of treated
and untreated mice. In the treated groups, paclitaxel
was injected intraperitoneally in a dose of 10 mg/kg on
the same day and a week after. Mice were weighed and
the tumor size was measured twice per week with an
electronic caliper. The volume was then computed by
considering the tumor as a sphere with the formula 4/3
(3.14 × r
3), r as the mean radius. Animals were eutha-
nized either when one of the diameters of the tumor
exceeded 17 mm, or if any potential suffering of the ani-
mal was observed or if weight loss exceeded 10%.
Results
TBCC protein expression in stable clones
Six stable clones of MCF7 cells overexpressing the pro-
tein TBCC (designated MC+) were established and char-
acterized compared to clones of control cells transfected
with the empty vector (designated as MP6). Among
these, three clones with high levels of TBCC, with
respect to three clones of control cells, were named
MC+1, MC+2 and MC+3 in decreasing order of expres-
sion and further explored (Figure 1). Three clones
obtained from MCF7 transfected with the empty vector
were designated MP6.1, MP6.2 and MP6.3 and used as
controls.
Impact of TBCC overexpression on the expression
level of related proteins
We have investigated the effect of TBCC overexpression
on the protein content of TBCD and ADP-ribosylation
factor-like 2 (Arl2) which are two essential partners of
TBCC in the folding pathway of a/b-tubulin dimers.
TBCD was increased in the MC+1 clone but not in the
two other clones MC+2 and MC+3. Conversely Arl2
was increased in the three clones of MC+ with respect
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we studied the expression level of the tumor suppressor
protein p53 and found that it was slightly increased in
the three clones of MC+ cells when compared to MP6
cells (Figure 1).
Influence of TBCC protein content on proliferation rate
When we tested by MTT assay the proliferation rate of
t h eM C + 1a n dM P 6 . 1c e l l sin vitro, we found that the
MC+1 cells had a slightly higher proliferation rate in
vitro than the control cells at 120 and 144 hours but
not at earlier timepoints. This result was visually con-
firmed by comparing the number of dividing cells
stained in blue due to the formation of formazan crys-
tals by their active mitochondria. These observations
were confirmed by quantification of the absorbance
optical density and the curve plotted (Figure 2A) shows
the significant differences between these two cell lines.
These results were confirmed on the MC+2, MC+3,
MP6.2 and MP6.3 clones. When we tested the prolifera-
tion rate of MC+1 and MP6.1 cells using the BrdU
incorporation assay, we found no significant difference
in the proliferation rate between the two clones. This
was confirmed on the other clones MC+2, MC+3,
MP6.2 and MP6.3 (Figure 2B).
Influence of TBCC protein content on cell cycle
distribution and mitotic duration
To explore if the difference in proliferation rates is cor-
related to a difference in the cell cycle distribution, we
investigated the percentage of cells in S and G2-M
phases by propidium iodide and flow cytometry in
MC+1 and MP6.1 cells (Figure 2C). We observed that
MC+1 cells had a lower percentage of cells in S-phase
11.7 ± 2.6 as compared to MP6.1 cells 16.7 ± 0.78, a
significant decrease of 30%, p < 0.05 (Figure 2C). This
difference was also accompanied by a higher percentage
of cells in G2-M phase 45 ± 3.9 as compared to the
MP6.1 30 ± 1.27, a significant increase of 50%, p < 0.05
(Figure 2C). This experiment was performed on the
MP6.2, MP6.3, MC+2 and MC+3 clones and the above
results were confirmed.
In order to correlate these phenotypic behaviours to
the increased content of TBCC protein, we inhibited the
protein expression of TBCC by transient transfection
using siRNA targetting TBCC in MP6.1 and MC+1
cells. The siRNA targetting TBCC we designed was vali-
dated by western blot on MCF7 cells. This sequence
inhibited TBCC (-48%, p < 0.01) compared to the
siRNA scrambled (data not shown) and was used to
inhibit TBCC in MC+1 and MP6.1. In both the MC+1
and MP6.1 cells, the inhibition of TBCC protein caused
a significant increase in percentage of cells in S-phase
and a significant decrease in percentage of cells in G2-
M phase (Figure 2C).
To explain the increased G2-M percentage observed
in MC+1 cells, we investigated the durations of
prophase-metaphase, anaphase-telophase and complete
mitosis in comparison to controls. We found that MC+1
cells took more time to complete mitosis (71 minutes as
Figure 1 Effect of tubulin binding cofactor C (TBCC) on the expression level of related proteins. Western blot analysis of total cell extracts
of the clones showing the effect of overexpression of TBCC on the expression level of TBCC, TBCD, Arl2 and p53. b-actin was used as a
reference protein. MC+1, MC+2 and MC+3 represent MCF7 cells stably transfected with pcDNA6/C+. MP6.1, MP6.2 and MP6.3 represent MCF7
cells stably transfected with empty pcDNA6.
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time was due mainly to longer anaphase-telophase dura-
tion as 37 minutes compared to 20 minutes in MP6.1
and not to a difference in the prophase-metaphase (Fig-
ure 2D). The cells overexpressing TBCC proceed slowly
through the mitosis which can be an explanation for the
high percentage of cells in G2-M phase of cell cycle.
In vivo progression of tumors
In order to study the impact of TBCC on tumorigen-
esis of breast cancer cells, we injected the six clones
MP6.1, MP6.2, MP6.3, MC+1, MC+2 and MC+3 into
SCID mice and monitored their in vivo progression
and tumor formation. The control clones were able to
form tumors of 200 to 250 mm
3one month later. How-
ever, the MC+ clones presented lower capacities of
growth in vivo with the tumors of volumes ranging
form 1 to 50 mm
3 (Figure 3).
Localisation of TBCC in the cytoplasm
The impact of TBCC overexpression on the cytoplasmic
distribution of TBCC was studied by immunofluores-
cence on MP6.1 and MC+1 cells. In a first step we
observed that the distribution of b-tubulins in the
Figure 2 Effect of TBCC on proliferation rate, cell cycle distribution and mitotic duration of MC+1 and MP6.1 cells. (A) Optical density of
absorbances measured at 540 and 690 nm of solubilized formazan crystals in MC+1 and MP6.1 formed after addition of MTT. The figure below
the graph represents the MC+1 and MP6.1-containing wells colored with formazan crystals after addition of methylthiazoletetrazolium (MTT)
every day for a total duration of one week. Results presented are the average values of three experiments. *: Values differ significantly from
MP6.1 at ≥ 95% confidence level by Student’s t-test. Bars represent standard deviation. (B) Proliferative capacity (BrdU labelling) of MC+1 and
MP6.1 cells for one week. Results presented are the average values of three experiments. Bars represent standard deviation. (C) Cell cycle
distribution of MC+1 and MP6.1 cells after incubation with propidium iodide. Percentage of cells in the S- and G2-M phase of the cell cycle in
MC+1, MP6.1, MC+1 + siRNA SCR, MC+1 + siRNA TBCC, MP6.1 + siRNA SCR and MP6.1 + siRNA TBCC. The cells represented as +siRNA SCR and
+siRNA TBCC are cells transiently double transfected with siRNA scrambled and siRNA targeting TBCC, respectively. Experiment was done 48
hours after first transfection. Results presented are the average values of three experiments. *: Values differ significantly at ≥ 95% confidence level
by Student’s t-test. Bars represent standard deviation. (D) Durations of prophase-metaphase, anaphase-telophase and complete mitosis in MC+1
and MP6.1 cells in minutes after 24 hours of time-lapse microscopic analysis. *: Values differ significantly from MP6.1 at ≥ 95% confidence level
by Student’s t-test. Bars represent standard deviation.
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TBCC. This was done by immunofluorescence using an
antibody against b-tubulin and the images show similar
cytoplasm staining between MP6.1 and MC+1 cells (Fig-
ure 4A). TBCC was similarly distributed in both nor-
mally and highly-expressing cells. The staining was
found to be cytoplasmic however it was not observed in
all cells of each cell line (Figure 4B). We found more
stained cells in MC+1 cells than in control cells. After
overlaying fluorescent images of TBCC with DAPI
images we observed that the cells that were strongly
stained for TBCC were cells in mitosis. This result sug-
gested that TBCC was more highly expressed in cells
undergoing mitosis. This was confirmed (Figure 4C) in
MC+1 cells exposed to paclitaxel 10 nM for 24 hours.
Paclitaxel is known to stabilize microtubules and causes
cell arrest in metaphase. We observed by immunofluor-
escence microscopy that the cells blocked in mitosis
were strongly stained with anti-TBCC antibody.
Effect of TBCC content on different tubulins and on
subcellular tubulin fractions
We studied the impact that TBCC overexpression might
have on the total a and b- t u b u l i n sa sw e l la so nd i f f e r -
ent posttranslational modifications of a-tubulin such as
acetylated, tyrosinated and detyrosinated (Glu) a-tubu-
lins and finally on the bIII-tubulin isotype. We observed
no significant difference in the expression of total a-
tubulin and tyrosinated a-tubulin between the clones
overexpressing TBCC and the controls (Figure 5A).
Regarding Glu a-tubulin and the bIII-tubulin, we
observed heterogeneity of expression among both the
clones of MP6 and MC+ which made impossible to con-
clude of a simple profile related to TBCC status (Figure
5A). However, concerning b-tubulin and acetylated a-
tubulin we observed an increase in expression in the
MC+ clones with respect to the MP6 clones.
In addition, we investigated the different pools of solu-
ble polymerizable ab-heterodimers (PT) and soluble
non-polymerizable tubulins (NPT) as well as the micro-
tubule tubulins (MT) in MC+1 and MP6.1 cells. The
different pools of tubulins were obtained after fractiona-
tion of MP6.1 and MC+1 lysates by series of ultracentri-
fugations. We have observed that the modification of
the TBCC level in MCF7 cells did not alter the total
pool of a-tubulin protein although it increased the total
pool of b-tubulin (Figure 5B). The overexpression of
TBCC protein strongly increased the NPT fraction and
strongly decreased the PT fraction, while it had only a
minor effect on the tubulin content of microtubules
which was slightly decreased. The profile of expression
of the NPT and PT fractions was similar for both the a-
tubulins and the b-tubulins but was less marked in the
case of a-tubulins (Figure 5B). Quantification of expres-
sion levels of a and b-tubulins in the different fractions
confirmed the results observed in the immunoblots
(Figure 5C).
Overexpression of TBCC decreases microtubule dynamics
The effects of overexpression of TBCC on microtubule
dynamic instability were determined in MC+1 cells 48 h
after transient transfection with pAcGFP1-a tubulin.
The microtubules in MC+1 cells grew and shortened
more slowly and for shorter lengths than those in
Figure 3 In vivo tumor progression. Progression of tumors growth measured at 2-3 days interval for one month after subcutaneous injections
of each of MC+1, MC+2, MC+3, MP6.1, MP6.2 and MP6.3 cells. Results presented are average values of three mice. Bars represent standard
deviation.
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Page 7 of 14MP6.1 cells and presented significantly less dynamicity.
The parameters for dynamic microtubules in MP6.1 and
MC+1 cells were determined (Table 1). The mean
growth rate was significantly decreased from 16.41 ±
1.99 μm/min in MP6.1 cells to 10.54 ± 0.37 μm/min in
MC+1 cells, corresponding to a decrease of 36%, p <
0.05. The mean shortening rate and the mean lengths of
individual growth and shortening were slightly
decreased. The mean shortening duration was slightly
increased compared to the mean growth duration and
mean pause duration that were significantly increased
from 0.15 ± 0.02 min and 0.25 ± 0.01 min in control
Figure 4 Localization of TBCC in MC+1 and MP6.1 cells. (A) Representative images of MC+1 and MP6.1 cells after DNA (DAPI, blue) and
b-tubulin (FITC, green) staining (B) Representative images of MC+1 and MP6.1 cells after DNA (DAPI, blue) and TBCC (FITC, green) staining (C)
Representative images of DNA (DAPI, blue) and TBCC (FITC, green) staining in MC+1 cells exposed 24 hours to 10 nM of paclitaxel.
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Page 8 of 14cells to 0.22 ± 0.01 min and 0.37 ± 0.02 min in MC+1
cells, an increase of 47%, p < 0.05 and 48%, p < 0.05,
respectively. The MC+1 cells presented a slower growth
movement than the control cells which is the cause of a
slow growth rate and a lower dynamicity. The frequen-
cies of catastrophe and rescue are important parameters
in studying the dynamicity of microtubules. The cata-
strophe frequency is the frequency with which the
microtubules switch from either pause or growth to
shortening. The rescue frequency is the frequency with
which the microtubules switch from shortening to either
growth or pause. As seen above, the MC+1 cells pre-
sented a shortening rate similar to that of the control
cells but with a decreased growth rate. This suggests
that the microtubules shortened in MC+1 cells are
either taking longer time to grow (high growth duration)
or staying in a pause phase (high pause duration). The
time-based catastrophe frequency was slightly increased
in MC+1 cells unlike the rescue frequency that was
increased significantly by 54%, p < 0.05 as compared to
control cells. This can be explained by the fact that the
microtubules of MC+1 cells have tiny movements of
growth and shortening for short distances (less than 0.5
μm) not counted in the growing and shortening events
and in the overall dynamicity of the microtubule. The
dynamicity was significantly decreased from 8.80 ± 1.02
μm/min in MP6.1 to 6.09 ± 1.06 μm/min in MC+1
cells. This decrease of 31%, p < 0.05 is representative of
less overall distances travelled by the microtubule either
in a growing or in a shortening event for 2 minutes.
In vitro response to Gemcitabine and antimicrotubule
compounds
Since TBCC is a major protein involved in the proper
folding pathway of tubulins into microtubules, we inves-
tigated the response of the TBCC overexpressing breast
cancer cells to antimicrotubule agents. These agents
block the cell cycle in G2-M phase. We incubated
MC+1 and MP6.1 cells 24 hours with non-toxic doses
of 10 nM paclitaxel or 1 nM vinorelbine, and observed
Figure 5 Effect of TBCC on different tubulins content and on subcellular tubulin fractions. (A) Western blot analysis of total cell extracts of
the MC+1, MC+2, MC+3, MP6.1, MP6.2 and MP6.3 clones showing the effect of overexpression of TBCC on the expression level of a-tubulin, b-
tubulin, tyrosinated a-tubulin, detyrosinated (glu) a-tubulin, b III-tubulin and acetylated a-tubulin. b-actin was used as a reference protein. (B)
Representative blots corresponding to the expression levels of a-tubulin and b-tubulin in nonpolymerizable tubulin heterodimers (NPT),
polymerizable tubulin (PT) heterodimers, microtubule heterodimers (MT) and total pool of tubulins in MC+1 and MP6.1 cells. These fractions
were obtained after series of ultracentrifugations. (C) Protein ratios (MC+1 vs. MP6.1) of both a-tubulins and b-tubulins levels in NPT, PT and MT
fractions. Results presented are the average values of three experiments. Bars represent standard deviation.
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to the G2-M blockage caused by these treatments with
respect to the MP6.1 cells. MC+1 cells presented 79 and
83% of cells in G2-M after paclitaxel and vinorelbine
exposure, respectively. The control cells were also
blocked but to a maximum percentage of 55% (Figure
6A). The percentage of MC+1 and MP6.1 cells in the
Sub-G0 phase of the cell cycle after 24 hours of treat-
ment with 10 nM of paclitaxel and 1 nM of vinorelbine
increased. However this increase was not statistically
significant and was slightly higher in MC+1 cells than in
MP6.1 cells (Figure 6B). In addition to antimicrotubule
agents, we investigated the response of the cells to gem-
citabine, an S-phase specific antimetabolite and we
found that MC+1 cells were less sensitive to gemcita-
bine than the MP6.1 cells, significantly at the dose of 1
nM (Figure 6C). These experiments were performed on
t h eM P 6 . 2 ,M P 6 . 3 ,M C + 2a n dM C + 3c l o n e sa n dt h e
above results were confirmed.
In vivo sensitivity to treatment
We injected the six clones MP6.1, MP6.2, MP6.3, MC+1,
MC+2 and MC+3 into SCID mice and monitored their in
vivo progression and tumor formation. The control clones
were able to form tumors unlike the MC+1, MC+2 and
MC+3 clones that presented lower capacities of growth
in vivo. When treated with paclitaxel, mice injected with
MC+ clones revealed higher sensitivity to the treatment
compared to mice injected with MP6 clones (Figure 6D).
Discussion
Tubulin binding cofactor C is a crucial protein for the
proper folding of a-a n db-tubulins to form heterodi-
mers able to polymerize into microtubules. In this
study, the major aim was to investigate the impact of
TBCC overexpression on the proliferation, cell cycle dis-
tribution and tumorigenesis of MCF7 cells as well as on
the microtubule contents and dynamics. Since the anti-
microtubule agents are common treatments for breast
cancer, we examined the response of our models to
these treatments both in vivo and in vitro. In addition to
this, expression levels of a and b tubulins were found to
be involved in predicting the response to treatments in
many cancers [22,23]. Some posttranslational modifica-
tions of a tubulins like detyrosination are of high occur-
rence in breast cancer [24]. This differential expression
level of tubulins in many cancers has made of them tar-
gets for treatments.
The overexpression of TBCC in MCF7 cells pro-
foundly altered the distribution of tubulin monomers
amongst cellular fractions and diminished the content
and dynamicity of their microtubules but did not pre-
vent the cells from completing mitosis and proliferating
correctly. We must insist however on the fairly low dif-
ferences in TBCC content observed between transfected
cells and controls, suggesting that higher levels of
expression may be incompatible with cell survival. Over-
expression of TBCC had a major impact on tubulin
fractions, with a large increase in the nonpolymerizable
fraction and a consequent decrease in the soluble tubu-
lin dimers fraction. The nonpolymerizable tubulin frac-
tion consists of the pool of tubulins in the a-tubulin/
TBCE/TBCC/TBCD/b-tubulin complex, the pool of a-
t u b u l i n sb o u n de i t h e rt oT B C Bo rT B C Eo rT B C E /
TBCC/TBCD/b-tubulin, and the pool of b-tubulins
bound either to TBCA or TBCD or a-tubulin/TBCE/
TBCC/TBCD. The reduced availability of a/b tubulins
to form polymerizable heterodimers may be due to the
fact that a large amount of the monomers is included in
TBCC-containing complexes. Of note and contrary to a
commonly accepted tubulin dogma, MC+ cells appear
to have disequilibrium between the contents of total a-
tubulin and b-tubulin. It is classically considered that
such disequilibrium would be lethal for mammalian
cells. However in this model the increased content can
be attributed to a specific enrichment in the non-func-
tional fraction of b-tubulin.
During mitosis, especially at the level of anaphase
chromosome movement, microtubules disassemble by
depolymerization and release free heterodimers. The
heterodimers released can be directly recruited by the
excess of TBCC in the cytoplasm. Indeed, TBCC
appears to be highly present in the cytoplasm during
mitosis as observed in cells blocked in mitosis by pacli-
taxel. We hypothesize that equilibrium exists between
the soluble amount of nonpolymerizable and polymer-
izable tubulins in MC+ cells and the cells’ requirement
for microtubules. We also observed a strong impact of
TBCC content on microtubule dynamics. At the onset
of mitosis the interphase microtubule network disas-
sembles while there is simultaneously a decrease in
Table 1 Parameters of microtubule dynamics in MC+1
and MP6.1 cells
Parameters MP6.1 MC+1 Change
Mean rate
(μm/min ± SE)
Growth 16.41 ± 1.99 10.54 ± 0.37 * -36%
Shortening 15.25 ± 2.14 14.35 ± 1.53
Mean length
(μm ± SE)
Growth 2.38 ± 0.49 2.14 ± 0.51
Shortening 2.40 ± 0.39 2.29 ± 0.10
Mean duration
(min ± SE)
Growth 0.15 ± 0.02 0.22 ± 0.01 * 47%
Shortening 0.16 ± 0.01 0.17 ± 0.01
Pause 0.25 ± 0.01 0.37 ± 0.02 * 48%
Mean frequency
(min
-1± SE)
Rescue 9.20 ± 0.53 14.20 ± 0.24 * 54%
Catastrophe 4.64 ± 0.70 5.38 ± 0.56
Dynamicity
(μm/min ± SE)
8.80 ± 1.02 6.09 ± 1.06 * -31%
*: Values differ significantly from MP6.1 at ≥ 95% confidence level by
Student’s t-test. Values are represented as mean ± SD
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microtubule dynamics [25]. In some cells, the increase
in dynamics is due to an increase in catastrophe
f r e q u e n c ya n dar e d u c t i o ni nt h er e s c u ef r e q u e n c y
rather than changes in growth and shortening rates
[26,27]. In our study, we found that the microtubules
in MC+1 cells grew and shortened more slowly and
for shorter periods of time than those in MP6.1 cells.
The dynamicity was significantly decreased in MC+1
cells in comparison to MP6.1 cells. These observations
are coherent with the tubulin fraction alterations
observed. The relative lack of available polymerizable
tubulin dimers could explain the reduced growing and
overall dynamicity.
The highly dynamic microtubules in the spindle are
required for all stages of mitosis [2]. During prometa-
phase, the dynamicity of microtubules is very important
in order to probe the cytoplasm and attach to chromo-
somes at their kinetochores [28]. Any single chromo-
some unable to attach to the spindle is enough to
prevent a cell from transitioning to anaphase and there-
fore be blocked at or before metaphase-anaphase transi-
tion and undergo apoptosis later on [29,30]. In our
study, the decreased dynamicity in MC+ cells did not
affect the prophase and metaphase progression and only
affected the anaphase-telophase transition. We observed
a significant increase in the duration of anaphase-telo-
p h a s ew h i c hi st h ec a u s eo fas l o w e rm i t o s i si nt h e
Figure 6 The influence of TBCC protein content on the response to treatment in vitro and in vivo.( A )T h eP e r c e n t a g eo fM C + 1a n d
MP6.1 cells in the G2-M phase of the cell cycle after 24 hours of treatment with 10 nM of paclitaxel and 1 nM of vinorelbine. Results presented
are the average values of three experiments. Bars represent standard deviation.*: Values differ significantly from MP6.1 at ≥ 95% confidence level
by Student’s t-test. (B) The ratio of treated vs. untreated MC+1 and MP6.1 cells in the Sub-G0 phase of the cell cycle after 24 hours of treatment
with 10 nM of paclitaxel and 1 nM of vinorelbine. The cell cycle was studied after incubation with propidium iodide. Results presented are the
average values of three experiments. Bars represent standard deviation. (C) Proliferative response by BrdU labelling (treated versus untreated
cells) after one week exposure to 0.5 and 1 nM of gemcitabine in MC+1 and MP6.1 cells. Results presented are the average values of three
experiments.*: Values differ significantly from MP6.1 at ≥ 95% confidence level by Student’s t-test. Bars represent standard deviation. (D)
Progression of tumors growth and response to paclitaxel measured at 2-3 days interval after subcutaneous injections of each of MC+1, MC+2,
MC+3, MP6.1, MP6.2 and MP6.3 cells at day 0 (empty arrow). At day 0 and day 7, paclitaxel was injected intraperitoneally in a dose of 10 mg/kg
(black arrow). Results presented are the mean values of the three mice, untreated or treated. Bars represent standard deviation.
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Page 11 of 14MC+ cells. This means that the less dynamic microtu-
bules affected the mitosis without causing blockage or
cell death. The distribution of MC+ cells in the cell
cycle was different from that of the control cells in that
they presented higher percentage of cells in the G2-M
phase and lower percentage in the S-phase. By inhibiting
TBCC protein through transient transfection of siRNA
targeting TBCC, we obtained an increase in the percen-
tage of cells in S-phase and a decrease in the percentage
of cells in G2-M, thereby confirming the involvement of
TBCC in the cell cycle alteration observed.
Previous publications have suggested that the dynami-
city of microtubules depends on microtubule composi-
tion and is correlated with post-translational
modifications of a-tubulins. Detyrosinated microtubules
(Glu microtubules) present enhanced stability against
end-mediated depolymerisation however the detyrosina-
tion alone is not sufficient to confer this enhanced stabi-
lity [31]. Tubulin detyrosination occurs frequently in
breast cancer and is linked to tumor aggressivity [24].
Reduced abundance of a and a-acetylated tubulin is
associated with enhanced apoptosis in leukemia cells
[32]. Acetylated a-tubulin is present in microtubules
that under depolymerising condition are more stable
than the majority of cytoplasmic microtubules [31,33].
The existence of a direct effect of acetylation on micro-
tubule stability and dynamics remains controversial [34].
In our study, we investigated the expression levels of
detyrosinated (Glu) a-tubulin, tyrosinated a-tubulin and
acetylated a-tubulin. Reproducible results were obtained
with the tyrosinated tubulin which was not modified
and for the acetylated tubulin that was increased in the
MC+ cells with respect to MP6 cells. The results of
increased expression level of acetylated a-tubulin in MC
+ cells can be explained as an attempt of these cells to
protect their microtubules. The microtubules in MC+
cells have diminished dynamicity and their reduced
growth rate is not enough to compensate for their con-
tinuous shortening events. As a means to prevent exces-
sive depolymerisation, the microtubules of MC+ might
have incorporated acetylated a t u b u l i ni no r d e rt o
acquire more stability against depolymerisation. It has
been previously reported that high expression of class
III beta tubulin by tumor cells is associated with resis-
tance to taxane chemotherapy in non-small cell lung
cancer [35]. Here we can’t do any correlation, since the
expression profile of the class III beta tubulin in our
models is not determined.
The MCF7 cells (human mammary adenocarcinoma)
emerge from an invasive ductal carcinoma type of can-
cer [36,37]. The in vivo invasiveness and metastasis pro-
cessing of MCF7 cells depend on many factors that
influence the cell such as steroid hormones, growth fac-
tors, oncogenes and tumor suppressor genes [38]. In our
study, MC+ cells presented a limited tumor growth in
vivo compared to MP6 cells. Since the proliferative
activity of MC+ cells in vitro was not reduced in com-
parison to control cells and their volume was not altered
(data not shown), we hypothesize that this reduced in
vivo g r o w t hm a yb ea tl e a s tp a r t i a l l ye x p l a i n e db yt h e
potential loss of aggressive and invasive capacities of
MC+ cells rather than by decreased proliferation rate
[39]. The study of expression levels of TBCC, a tubulin
and b tubulin in the tumors extracted from the mice
revealed that the MC+ cells maintained the same altera-
tions in vivo as those reported in vitro (data not shown).
In the intent to understand the potential involvement of
T B C Ci nt h ei n v a s i v e n e s sp h e n o t y p e ,w eh a v es t u d i e d
by quantitative RT-PCR the levels of expression of the
TBCC gene in thirteen different human breast cancer
cell lines for which in vitro invasiveness properties have
been reported [40]. We found that the four cell lines
that expressed TBCC the highest (MCF7, MDA-MB361,
MDA-MB453 and UACC812) were the ones with low in
vitro invasiveness capacity and the other nine cell lines
that were highly invasive had low TBCC expression
(Additional file 1). While this observation does not
allow us to conclude a direct role of TBCC it suggests a
possible involvement of TBCC in tumor aggressivity
whether through microtubules or through other uniden-
tified pathways such as interaction with the Arl2 pro-
tein. It is important to note that in the cells
overexpressing TBCC we noticed that the expression
levels of Arl2 and tumor suppressor p53 were slightly
increased. ADP ribosylation factor like 2 (Arl2) protein
is a GTPase that belongs to ADP ribosylation factor
(ARF) family [41,42] and plays a role in microtubule
dynamics [21,42]. Arl2 is known to directly bind to
T B C Da n dc a ni n h i b i tT B C Df r o md i s s o c i a t i n gt h ea/b
tubulin heterodimers [17]. MCF7 cells overexpressing
Arl2 were found to have low inv i v ogrowth capacity
[43]. However in vitro,t h eb e h a v i o u ro fM C +c e l l si n
terms of cell cycle, microtubule dynamics, response to
antimicrotubule agents larg e l yd i f f e rf r o mt h a to fc e l l s
overexpressing Arl2 [21]. Therefore one possible
hypothesis could be that in vivo a mechanism involving
TBCC and p53 or an interaction between Arl2 and
TBCC is involved in the loss of aggressivity of MC+
cells.
Based on the success and efficiency of microtubule-
targeted drugs in the treatments of cancer in general
and breast cancer in specific, microtubules remain the
best cancer target identified to date [44]. Even though
paclitaxel and vinorelbine have different mechanisms of
action with respect to microtubule, their cellular effects
at low but clinically relevant concentrations are reduced
microtubule dynamics inducing mitotic arrest. Paclitaxel,
from the taxanes family binds to b-tubulin, causes
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Page 12 of 14lateral polymerization and suppresses microtubule
dynamics [45]. The cellular effect of paclitaxel at low
concentrations (<10 nM) include suppression of micro-
tubule dynamics without affecting microtubule content
and mitotic arrest then apoptosis [46]. Vinorelbine, from
the vinca alkaloids binds with high affinity to the plus
end of the microtubule and with low affinity to the sides
of the microtubule and leads to depolymerization
[46,47]. However at low concentrations, vinca alkaloids
block mitosis with little or no depolymerisation of spin-
dle microtubules [48]. Therefore, compounds that depo-
lymerize microtubules can also stabilize microtubule
dynamics at relatively low concentrations [49]. In our
study, we have observed an increased sensitivity of the
MC+ cells in vitro toward the mitosis blockage com-
pared to MP6 cells. The low non toxic concentrations
of both paclitaxel (10 nM) and vinorelbine (1 nM)
induced a stronger G2-M block in MC+ cells than in
MP6 cells. We used subtoxic concentrations of treat-
ments as shown by the absence of significant increase in
percentage of sub-G0 cells. The results observed were
homogenous in the three clones of each cell line. The
enhanced sensitivity of MC+ cells to paclitaxel was con-
firmed in vivo. We explain the increased sensitivity of
the MC+ for the antimicrotubule agents by two main
hypotheses. One is the basal lower dynamicity of micro-
tubules in these cells compared to MP6 cells. Second is
the high percentage of G2-M cells in MC+ cells which
means high percentage of target cells for antimicrotu-
bule agents. These results suggest that TBCC content of
breast tumor cells significantly influences their sensitiv-
ity to tubulin binding agents both in vitro and in vivo.
When we tested the response of MC+1 and MP6.1 cells
to gemcitabine, a nucleoside analog and S-phase specific
antimetabolite, we showed that MC+1 cells were less
sensitive to gemcitabine than the MP6.1 cells, signifi-
cantly at 1 nM. This lower sensitivity to gemcitabine is
due to the fact that MC+1 cells present a lower percen-
tage of cells in the S-phase at the basal level. The differ-
ential responses to antimicrotubule agents and
gemcitabine reveal that our cell models respond to these
treatments based on their distribution in the cell cycle.
Therefore we suggest that other anticancer treatments
that target the cell cycle can have interesting effects on
our cell models.
Conclusion
Our results suggest that the overexpression of TBCC
protein in MCF7 cells influences their tubulin pools and
microtubule dynamics, with important consequences in
terms of mitotic progression, tumor growth and sensi-
tivity to antimicrotubule agents. Moderately increased
TBCC content was associated with an increase in the
nonpolymerizable tubulin pool and reduced microtubule
dynamics. This was associated with prolonged anaphase-
telophase and reduced growth in vivo. The higher per-
centage of cells in G2-M phase of the cell cycle made of
the MC+ cells better targets for antimicrotubule agents.
These results underline the importance of the microtub-
ular network in the tumor cell aggressivity phenotype.
While currently available compounds mostly target
microtubule dynamics, another possibility could be to
alter tubulin pools in tumor cells. Another perspective
for these results would be to look for potential partners
of TBCC. It would be interesting to investigate if TBCC
interacts or binds with microtubule binding proteins
and to try to synthesize a ligand that can stabilize this
protein inside the cytoplasm so that it would be con-
tinuously active.
Additional file 1: Correlation between TBCC expression level and in
vitro invasive capacity of breast cancer cell lines. Values of gene
expression are calculated with respect to the TBCC expression level in
HME cells (human mammary epithelial cells). The cDNA levels were
normalized to the expression of the 18S ribosomal gene as previously
described by Saussede-Aim et al. 2009. Saussede-Aim J, Matera EL,
Herveau S, Rouault JP, Ferlini C, Dumontet C: Vinorelbine Induces b3-
Tubulin Gene Expression through an AP-1 Site. Anticancer research
2009, 29:3003-3009.
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